On Friday, Esperion Therapeutics Inc (NASDAQ: ESPR) opened lower -1.10% from the last session, before settling in for the closing price of $1.81. Price fluctuations for ESPR have ranged from $1.58 to $3.94 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 9.55%. Company’s average yearly earnings per share was noted 85.44% at the time writing. With a float of $195.08 million, this company’s outstanding shares have now reached $195.44 million.
Considering the fact that the conglomerate employs 240 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 81.57%, operating margin of 5.57%, and the pretax margin is -29.37%.
Esperion Therapeutics Inc (ESPR) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Esperion Therapeutics Inc is 0.99%, while institutional ownership is 65.91%. The most recent insider transaction that took place on Jan 17 ’25, was worth 20. In this transaction Chief Financial Officer of this company sold 9 shares at a rate of $2.27, taking the stock ownership to the 240,682 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Commercial Officer sold 123 for $2.26, making the entire transaction worth $278. This insider now owns 159,998 shares in total.
Esperion Therapeutics Inc (ESPR) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 85.44% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Check out the current performance indicators for Esperion Therapeutics Inc (ESPR). In the past quarter, the stock posted a quick ratio of 1.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.01 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Compared to the last year’s volume of 5.24 million, its volume of 5.2 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 6.08%. Additionally, its Average True Range was 0.17.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 8.90%, which indicates a significant increase from 7.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.56% in the past 14 days, which was lower than the 88.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.4163, while its 200-day Moving Average is $2.1962. Nevertheless, the first resistance level for the watch stands at $1.8300 in the near term. At $1.8700, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.9150. If the price goes on to break the first support level at $1.7450, it is likely to go to the next support level at $1.7000. Should the price break the second support level, the third support level stands at $1.6600.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
There are currently 197,035K shares outstanding in the company with a market cap of 352.69 million. Presently, the company’s annual sales total 116,330 K according to its annual income of -209,250 K. Last quarter, the company’s sales amounted to 51,630 K and its income totaled -29,520 K.
